NeuroMetrix Announces Quell Now Available on Amazon.com through Amazon Launchpad
December 07 2016 - 12:05PM
Business Wire
NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today
that the Company’s Quell® Wearable Pain Relief device is now
available on Amazon Launchpad.
Amazon Launchpad is a program that makes it easy for startups to
launch, market, and distribute their products to hundreds of
millions of Amazon customers across the globe. Amazon Launchpad has
worked with over 100 leading venture capital firms, startup
accelerators, and crowd-funding platforms to help more than 1,000
startups launch products in the U.S., U.K., China, Germany, France,
and Canada. To shop the Amazon Launchpad store, visit
www.amazon.com/launchpad.
“We are excited that Quell is now being sold on Amazon.com
through the Amazon Launchpad program,” said Frank McGillin, Senior
Vice President and Chief Commercial Officer of NeuroMetrix. “This
allows for additional educational content for consumers, and now
that Quell is shipped and sold by Amazon, customers can take
advantage of the fast, free shipping benefits of Amazon Prime.”
About Quell
Quell is designed for millions of people suffering from chronic
pain. The advanced wearable device is lightweight and can be worn
during the day while active, and at night while sleeping. It has
been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users
reported an improvement in their chronic pain. Quell users can
start, stop, and adjust therapy discreetly via the optional Quell
Relief app. Quell also offers advanced sleep tracking that provides
feedback on eight dimensions of sleep including sleep duration,
quality, body position, time out of bed, and repetitive leg
movements throughout the night. Quell was the winner of the
2016 SXSW (South by Southwest) Innovation Award for Best
Wearable Technology. Quell is available at select healthcare
professionals and retailers. Visit QuellRelief.com for
more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep
disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs, including a therapeutic device for restless leg syndrome.
The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health
Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207005959/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024